Issued Patents All Time
Showing 51–75 of 132 patents
| Patent # | Title | Co-Inventors | Date |
|---|---|---|---|
| 10828353 | Compositions and methods for T cell delivery of therapeutic molecules | Yangbing Zhao, Xiaojun Liu | 2020-11-10 |
| 10829735 | Methods for improving the efficacy and expansion of immune cells | Felipe Bedoya, Saba Ghassemi, Omkar U. Kawalekar, Bruce L. Levine, Jan J. Melenhorst +3 more | 2020-11-10 |
| 10800840 | Compositions and methods for generating a persisting population of T cells useful for the treatment of cancer | Matthew J. Frigault, Yangbing Zhao, John Scholler | 2020-10-13 |
| 10696749 | Enhancing activity of CAR T cells by co-introducing a bispecific antibody | Yangbing Zhao, Xiaojun Liu | 2020-06-30 |
| 10640569 | Human mesothelin chimeric antigen receptors and uses thereof | Gregory Beatty, Boris Engels, Neeraja Idamakanti, Andreas Loew, Huijuan Song +1 more | 2020-05-05 |
| 10603378 | Toxicity management for anti-tumor activity of CARs | Bruce L. Levine, Michael D. Kalos, Stephan Grupp | 2020-03-31 |
| 10577407 | Use of ICOS-based CARS to enhance antitumor activity and CAR persistence | Sonia Guedan Carrio, Yangbing Zhao, John Scholler | 2020-03-03 |
| 10577417 | Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy | Gregory Beatty, Boris Engels, Neeraja Idamakanti, Andreas Loew, Michael C. Milone +3 more | 2020-03-03 |
| 10501519 | Use of the CD2 signaling domain in second-generation chimeric antigen receptors | John Scholler, Avery D. Posey | 2019-12-10 |
| 10421960 | RNA engineered T cells for the treatment of cancer | Yangbing Zhao | 2019-09-24 |
| 10357514 | Treatment of cancer using anti-CD19 Chimeric Antigen Receptor | David L. Porter, Marcela Maus, Mariusz A. Wasik, Saar Gill, Joseph A. Fraietta +11 more | 2019-07-23 |
| 10329355 | Compositions and methods for targeting stromal cells for the treatment of cancer | Ellen Puré, Liang-Chuan Wang, Steven M. Albelda, John Scholler | 2019-06-25 |
| 10308717 | Treatment of cancer using humanized anti-EGFRvIII chimeric antigen receptor | Jennifer Brogdon, Laura Alexandra Johnson, Andreas Loew, Marcela Maus, John Scholler +1 more | 2019-06-04 |
| 10286066 | Artificial antigen presenting cells and uses thereof | James L. Riley, Robert Vonderheide, Nicole Aqui, Megan Davis | 2019-05-14 |
| 10273300 | Methods of making chimeric antigen receptor-expressing cells | Felipe Bedoya, Saba Ghassemi, Bruce L. Levine, Jan J. Melenhorst, Michael C. Milone +2 more | 2019-04-30 |
| 10253086 | CD20 therapies, CD22 therapies, and combination therapies with a CD19 chimeric antigen receptor (CAR)-expressing cell | Hans Bitter, Jennifer Bordeaux, Barbara Brannetti, Jennifer Brogdon, Naveen Dakappagari +12 more | 2019-04-09 |
| 10221245 | Treatment of cancer using humanized anti-CD19 chimeric antigen receptor | Jennifer Brogdon, Andreas Loew, Marcela Maus, John Scholler | 2019-03-05 |
| 10174095 | Nucleic acid encoding a humanized anti-BCMA chimeric antigen receptor | Jennifer Brogdon, Eugene Choi, Hilmar Erhard Ebersbach, David Glass, Heather Huet +9 more | 2019-01-08 |
| 10117896 | Use of a trans-signaling approach in chimeric antigen receptors | Daniel J. Powell, Jr. | 2018-11-06 |
| 10046008 | Methods for treating chronic lymphocytic leukemia (CLL) | Bruce L. Levine, Anne Chew, Stephen J. Schuster | 2018-08-14 |
| 10040846 | Compositions and methods for generating a persisting population of T cells useful for the treatment of cancer | Matthew J. Frigault, Yangbing Zhao, John Scholler | 2018-08-07 |
| 9994818 | ICOS critically regulates the expansion and function of inflammatory human Th17 cells | James L. Riley, Chrystal Paulos, Bruce L. Levine | 2018-06-12 |
| 9783591 | Use of the CD2 signaling domain in second-generation chimeric antigen receptors | John Scholler, Avery D. Posey | 2017-10-10 |
| 9765156 | Enhancing activity of CAR T cells by co-introducing a bispecific antibody | Yangbing Zhao, Xiaojun Liu | 2017-09-19 |
| 9714278 | Use of ICOS-based CARs to enhance antitumor activity and CAR persistence | Sonia Guedan Carrio, Yangbing Zhao, John Scholler | 2017-07-25 |